title: Visfatin stimulates proliferation of MCF-7 human breast cancer cells.
abstract: Obesity, a condition characterized by increased fat content and altered secretion of adipokines, is a risk factor for postmenopausal breast cancer. Visfatin has recently been established as a novel adipokine that is highly enriched in visceral fat. Here we report that visfatin regulated proliferation of MCF-7 human breast cancer cells. Exogenous administration of recombinant visfatin increased cell proliferation and DNA synthesis rate in MCF-7 cells. Furthermore, visfatin activated G1-S phase cell cycle progression by upregulation of cyclin D1 and cdk2 expression. Visfatin also increased the expression of matrix metalloproteinases 2, matrix metalloproteinases 9, and vascular endothelial growth factor genes, suggesting that it may function in metastasis and angiogenesis of breast cancer. Taken together, these findings suggest that visfatin plays an important role in breast cancer progression.
authors.affiliation: Department of Biological Sciences, College of Natural Sciences, University of Ulsan, Ulsan, 680-749, Korea.
authors.forename: Jae Geun
authors.initials: JG
authors.lastname: Kim
authors.forename: Eun Ok
authors.initials: EO
authors.lastname: Kim
authors.forename: Bo Ra
authors.initials: BR
authors.lastname: Jeong
authors.forename: Young Joo
authors.initials: YJ
authors.lastname: Min
authors.forename: Jeong Woo
authors.initials: JW
authors.lastname: Park
authors.forename: Eun Sook
authors.initials: ES
authors.lastname: Kim
authors.forename: Il Seong
authors.initials: IS
authors.lastname: Namgoong
authors.forename: Young Il
authors.initials: YI
authors.lastname: Kim
authors.forename: Byung Ju
authors.initials: BJ
authors.lastname: Lee
mesh_terms: D017667:Adipocytes / Q000378:metabolism; D054392:Adipokines / Q000494:pharmacology; D052436:Adipose Tissue, White / Q000378:metabolism / Q000473:pathology; D015992:Body Mass Index; D001973:Bromodeoxyuridine / Q000032:analysis; D018270:Carcinoma, Ductal, Breast / Q000378:metabolism* / Q000473:pathology; D002453:Cell Cycle / Q000187:drug effects*; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects*; D019938:Cyclin D1 / Q000378:metabolism; D051357:Cyclin-Dependent Kinase 2 / Q000378:metabolism; D016213:Cyclins / Q000378:metabolism; D005260:Female; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects*; D006801:Humans; D020778:Matrix Metalloproteinase 2 / Q000378:metabolism; D020780:Matrix Metalloproteinase 9 / Q000378:metabolism; D054409:Nicotinamide Phosphoribosyltransferase / Q000008:administration & dosage / Q000494:pharmacology*; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000235:genetics; D015398:Signal Transduction / Q000187:drug effects*; D015854:Up-Regulation; D042461:Vascular Endothelial Growth Factor A / Q000378:metabolism
chemical_list: D054392:Adipokines; D016213:Cyclins; D011994:Recombinant Proteins; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D019938:Cyclin D1; D054409:Nicotinamide Phosphoribosyltransferase; C495894:CDK2 protein, human; D051357:Cyclin-Dependent Kinase 2; D020778:Matrix Metalloproteinase 2; D020780:Matrix Metalloproteinase 9; D001973:Bromodeoxyuridine